Colorado unapproved drug and dietary supplement makers ordered to cease operations for federal violations
Dietary supplement products "misbranded" and unapproved new drugs being marketed with drug claims despite not being approved for any use.
US District Judge Marcia S. Krieger for the US District Court for Colorado entered a consent decree of permanent injunction against EonNutra LLC, CDSM LLC and HABW LLC, manufacturers and distributors of unapproved drugs and dietary supplements, and their owner, Michael Floren, requiring Floren's businesses to immediately cease operations until they come into compliance with federal laws.
Floren marketed products on many websites, including www.sotosupplements.com, www.deerantlermax.com, www.warhorselabs.com, www.primalragenutrition.com and www.dnnutrition.com. In addition, his products were sold in a retail location in Colorado Springs, Colorado.
"Companies that market their products with unproven health claims and continue to violate manufacturing regulations put consumers' health in jeopardy," said Melinda Plaisier, FDA associate commissioner for regulatory affairs. "The FDA will take the enforcement actions necessary to protect consumers from this undue risk."
The FDA inspected Floren's businesses, which shared a location, four times since 2012. Despite assurances from Floren that the deficiencies noted during the inspections would be corrected, follow-up FDA inspections revealed that Floren repeatedly failed to make the necessary corrections.
Over the course of the inspections, the FDA determined Floren's dietary supplement products to be misbranded and unapproved new drugs because they were being marketed with drug claims despite not being approved for any use. Some of the claims Floren's dietary supplement products were marketed with included the treatment of high cholesterol, hypertension, diabetes, depression and muscle pain.
During the inspections, FDA investigators also found Floren's businesses were manufacturing and distributing misbranded and adulterated dietary supplements. Numerous violations of the agency's current Good Manufacturing Practice (cGMP) regulations for dietary supplements were found, including failure to establish specifications for dietary supplement components and failure to test or verify that components and finished products meet product specifications for identity, purity, strength or composition. Because Floren's businesses failed to follow cGMP regulations, their dietary supplements are adulterated under the Federal Food, Drug, and Cosmetic Act. Some of the supplements were also misbranded because Floren's businesses failed to properly list on the products' label the number of servings per container and the correct serving size per container. Additionally, they failed to list each ingredient contained in the dietary supplements and identify the part of the plant each botanical dietary ingredient was derived from.
The consent decree prohibits Floren and his businesses from marketing misbranded or unapproved new drugs and adulterated or misbranded dietary supplements. Before Floren and his businesses can resume operations, they must, among other things, recall their dietary supplements, hire labelling and good manufacturing practices experts and receive written permission from the FDA to resume operations.
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance